These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18941440)

  • 1. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.
    Hauck B; Murphy SL; Smith PH; Qu G; Liu X; Zelenaia O; Mingozzi F; Sommer JM; High KA; Wright JF
    Mol Ther; 2009 Jan; 17(1):144-52. PubMed ID: 18941440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
    Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
    Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
    Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
    J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
    Wang L; Figueredo J; Calcedo R; Lin J; Wilson JM
    Hum Gene Ther; 2007 Mar; 18(3):185-94. PubMed ID: 17324107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
    Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
    Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production.
    Halbert CL; Metzger MJ; Lam SL; Miller AD
    Gene Ther; 2011 Apr; 18(4):411-7. PubMed ID: 21160534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.
    Shao W; Earley LF; Chai Z; Chen X; Sun J; He T; Deng M; Hirsch ML; Ting J; Samulski RJ; Li C
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.
    He Y; Weinberg MS; Hirsch M; Johnson MC; Tisch R; Samulski RJ; Li C
    Hum Gene Ther; 2013 May; 24(5):545-53. PubMed ID: 23534873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.
    Wu TL; Li H; Faust SM; Chi E; Zhou S; Wright F; High KA; Ertl HC
    Mol Ther; 2014 Jan; 22(1):42-51. PubMed ID: 24077034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype.
    Grimm D; Pandey K; Nakai H; Storm TA; Kay MA
    J Virol; 2006 Jan; 80(1):426-39. PubMed ID: 16352567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo.
    Li C; Hirsch M; Asokan A; Zeithaml B; Ma H; Kafri T; Samulski RJ
    J Virol; 2007 Jul; 81(14):7540-7. PubMed ID: 17475652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.
    Aldrich WA; Ren C; White AF; Zhou SZ; Kumar S; Jenkins CB; Shaw DR; Strong TV; Triozzi PL; Ponnazhagan S
    Gene Ther; 2006 Jan; 13(1):29-39. PubMed ID: 16136165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement is an essential component of the immune response to adeno-associated virus vectors.
    Zaiss AK; Cotter MJ; White LR; Clark SA; Wong NC; Holers VM; Bartlett JS; Muruve DA
    J Virol; 2008 Mar; 82(6):2727-40. PubMed ID: 18199646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
    Finn JD; Hui D; Downey HD; Dunn D; Pien GC; Mingozzi F; Zhou S; High KA
    Mol Ther; 2010 Jan; 18(1):135-42. PubMed ID: 19904235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia.
    Hauck B; Xu RR; Xie J; Wu W; Ding Q; Sipler M; Wang H; Chen L; Wright JF; Xiao W
    Hum Gene Ther; 2006 Jan; 17(1):46-54. PubMed ID: 16409124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.
    Mori S; Wang L; Takeuchi T; Kanda T
    Virology; 2004 Dec; 330(2):375-83. PubMed ID: 15567432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
    Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
    Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.